- Home
- ATNI vs FBRX Comparison
ATNI vs FBRX Comparison
Compare ATNI & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATNI | FBRX |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.5M | 487.2M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ATNI | FBRX |
|---|---|---|
| Price | $27.03 | $22.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 49.4K | ★ 194.1K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | 34.29 | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $727,975,000.00 | $36,000.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.76 | $7.78 |
| 52 Week High | $30.45 | $35.80 |
Technical Indicators
Market Signals| Indicator | ATNI | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.89 | 40.01 |
| Support Level | $21.15 | $10.38 |
| Resistance Level | $27.66 | $22.61 |
| Average True Range (ATR) | 1.26 | 2.22 |
| MACD | -0.01 | -0.51 |
| Stochastic Oscillator | 78.55 | 27.81 |
Price Performance
Historical ComparisonAbout ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.